FAQs About Recombinant Testing Validation

Practical applications and updated regulations for this promising alternative

Endotoxin testing ensures the safety of pharmaceuticals and medical devices by detecting bacterial endotoxins. Traditionally, this relied on Limulus Amebocyte Lysate (LAL), an animal-derived reagent. Recombinant alternatives, such as Recombinant Cascade Reagent (rCR) and Recombinant Factor C (rFC), eliminate the need for animal-derived materials. rCR replicates the natural endotoxin detection cascade, ensuring broad sensitivity, while rFC uses a single-protein fluorescence-based approach that may require additional equipment and procedural adjustments. With the introduction of USP Chapter <86>, regulatory acceptance of recombinant methods has expanded, prompting more laboratories to explore these alternatives.

To provide expert insight, Jordi Iglesias, a Scientific Portfolio Specialist at Charles River’s Microbial Solutions team, answers key questions on validating recombinant endotoxin testing. With nearly 15 years of experience in microbiology and aseptic lab management, Jordi discusses regulatory compliance, validation requirements, and best practices to help laboratories transition smoothly while ensuring accuracy, efficiency, and sustainability

What are the validation requirements for recombinant endotoxin testing, and how do they differ from traditional LAL methods?

Jordi: The validation requirements for recombinant technologies like rCR differ from traditional LAL methods because compendial methods assume predefined parameters will work with all products. For alternative methods, each product requires testing additional parameters to ensure compatibility. Compendial methods require method suitability testing to demonstrate product compatibility, often through interference testing. In contrast, rCR requires validation of parameters like accuracy, repeatability, intermediate precision, robustness, and equivalency, as these cannot be assumed to work universally. This means labs using rCR must invest additional time in validation to account for these factors. While it may seem more complex, it ensures accuracy and reliability tailored to the specific product.

What are the biggest challenges in validating recombinant endotoxin testing methods, and how can labs overcome them?

Jordi: The challenges can fall into two categories: lab work and regulatory compliance. In the lab you need to perform the validation and then send the validation out to be reviewed and accepted by regulatory agencies. Validation for water testing is straightforward, thanks to primary validation packages provided by vendors that cover many parameters. However, final product testing requires validation with the actual product matrix, which adds a little more complexity. Submitting validation data for approval in multiple markets can be time-consuming, especially when addressing questions and waiting for approvals. Companies selling in 100+ countries face significant administrative hurdles. So, it's not difficult, but it is time consuming. Going back to the first question about challenges besides these, I think customers have a mindset where they think that compendial is better than alternative, that alternative is something strange, but alternative methods are completely accepted by the pharmacopeia. A compendial method was an alternative before being compendial. It's a process we need to perform to ease the transition. 

How does the accuracy of environmental endotoxin recovery using rCR compare to traditional LAL methods?

Jordi: Studies, such as one by Dr. Kikuchi, highlighted key differences. In this study, rCR achieves a mean recovery rate of approximately 79% for environmental endotoxins by contrast, rFC demonstrates lower recovery rates, around 32%, compared to traditional LAL. This is the experience that we have. We see that some recombinants are a little bit below LAL, but one factor contributing to rCR’s higher recovery is the inclusion of Factor B, an enzyme crucial for endotoxin detection, which rFC lacks. This scientific advantage makes rCR a more reliable choice for accurate environmental endotoxin recovery.

What resources and support are available to help labs transition to recombinant endotoxin testing?

Jordi: Transitioning to recombinant testing is significantly easier with comprehensive validation packages. These packages provide clear instructions for validating remaining parameters, detailed calculation spreadsheets, and structured protocols. They simplify the process, enabling labs to complete validation efficiently and with confidence. I think that this is what makes the difference. Given the workload of QC professionals managing multiple responsibilities, having ready-to-use tools, and expert guidance is invaluable. While regulatory approvals ultimately depend on reviewers, these resources maximize success and minimize effort.

What are the most important factors when moving to animal-free endotoxin testing, and how can labs ensure compliance?

Jordi: This is a great question. I believe the key factors are compliance, quality, and sustainability. You cannot use a very sustainable solution that has no quality or compliance. 

• Compliance: Labs must ensure the methodology meets global market requirements. For example, rFC is compendial for water testing in Europe but requires alternative validation for final products. Using non-compliant methods can pose serious business risks.
• Quality: Alternative methods like rCR must match or exceed traditional methods in performance. Comprehensive validation ensures compliance with all market requirements, providing consistent quality across regions.
• Sustainability: Moving to animal-free testing supports environmental goals and business continuity. With climate change potentially impacting animal populations, having alternative options is critical. 

For rCR, using our approach combined with our primary validation package, our protocols and spreadsheets will help customers streamline the process. You can validate an alternative method in a short period of time, and you will comply with all market requirements. You will not have different validation requirements for market A or market B. Following the validation approach that we suggest, you will comply with all market requirements with one validation, and you will be covered in all markets.

How have other laboratories successfully integrated rCR into routine endotoxin testing, and what best practices can be applied?

Jordi: The rollout of rCR is still in its early stages because we launched vials in July 2023 and cartridges in January 2024. While direct experience with regulatory agency feedback is limited, comprehensive primary validation packages and expert support can mitigate potential roadblocks. Early adopters highlight the importance of proactive planning to integrate rCR into routine workflows successfully.

Elizabeth Noble is a Senior Strategic Marketing Specialist for Charles River.

The Micro Keeps You in The Know
You don't need an agar plate to grow your microbial knowledge. Get industry updates, articles and other resources delivered straight to your inbox each month.
Subscribe